Sosei Group Corporation (JP:4565)
:4565
4565 Stock Chart & Stats
¥862.00
-¥10.00(-0.99%)
At close: 4:00 PM EST
¥862.00
-¥10.00(-0.99%)
Day’s Range― - ―
52-Week Range¥668.00 - ¥1,048.00
Previous CloseN/A
Volume458.60K
Average Volume (3M)945.56K
Market Cap
¥91.85B
Enterprise Value¥127.78B
Total Cash (Recent Filing)¥20.36B
Total Debt (Recent Filing)¥57.38B
Price to Earnings (P/E)―
Beta0.99
Next Earnings
May 01, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-85.49
Shares Outstanding90,496,735
10 Day Avg. Volume1,166,890
30 Day Avg. Volume945,556
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)1.22
Price to Sales (P/S)2.52
P/FCF Ratio-23.96
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)25.77
Revenue Forecast (FY)¥38.18B
Bulls Say, Bears Say
Bulls Say
GPCR Structure-based PlatformSosei’s specialized GPCR structure‑based discovery platform (Sosei Heptares) is a durable competitive asset: it generates repeatable discovery collaborations, supports out‑licensing and milestone economics, and creates a differentiated technical moat that sustains partner demand over multi‑year horizons.
Commercial Product MomentumStrong commercial execution with PIVLAZ market leadership and rapid QUVIVIQ growth builds a predictable revenue base. The commercial unit returned to core profitability, providing durable cash generation and de‑risking reliance on platform milestones while supporting reinvestment in pipeline and business development.
Phase II‑ready Pipeline AssetsHaving multiple Phase II‑ready in‑house programs increases optionality for high‑value BD deals and milestone/royalty streams. These nearer‑term clinical assets materially enhance monetization prospects and strategic flexibility versus a purely discovery‑stage portfolio, improving medium‑term revenue visibility if deals are executed.
Bears Say
Losses And Negative Cash FlowPersistent material losses and negative operating/free cash flow weaken financial resilience. Continued cash burn increases reliance on external funding or asset monetization, constrains strategic optionality, and raises execution risk if projected cost savings or BD milestones do not materialize within the next 2–6 months.
Increased LeverageLeverage rising to ~1.0x debt/equity reduces balance sheet flexibility while losses persist. Higher debt elevates refinancing and covenant risk, limits ability to fund R&D or make opportunistic BD moves, and increases the impact of cash‑flow shortfalls on long‑term strategic execution.
Milestone/BD Revenue UncertaintyA meaningful share of revenues is milestone‑driven and partner dependent, making cash flows lumpy and planning harder. Tougher BD conditions and higher data demands prolong deal cycles, meaning the company’s revenue upside is conditional and could delay expected milestone gains and licensing outcomes.
Sosei Group News
4565 FAQ
What was Sosei Group Corporation’s price range in the past 12 months?
Sosei Group Corporation lowest stock price was ¥668.00 and its highest was ¥1048.00 in the past 12 months.
What is Sosei Group Corporation’s market cap?
Sosei Group Corporation’s market cap is ¥91.85B.
When is Sosei Group Corporation’s upcoming earnings report date?
Sosei Group Corporation’s upcoming earnings report date is May 01, 2026 which is in 24 days.
How were Sosei Group Corporation’s earnings last quarter?
Sosei Group Corporation released its earnings results on Feb 13, 2026. The company reported -¥85.49 earnings per share for the quarter, missing the consensus estimate of ¥73.9 by -¥159.39.
Is Sosei Group Corporation overvalued?
According to Wall Street analysts Sosei Group Corporation’s price is currently Overvalued.
Does Sosei Group Corporation pay dividends?
Sosei Group Corporation pays a Notavailable dividend of ¥2.5 which represents an annual dividend yield of N/A. See more information on Sosei Group Corporation dividends here
What is Sosei Group Corporation’s EPS estimate?
Sosei Group Corporation’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Sosei Group Corporation have?
Sosei Group Corporation has 90,496,735 shares outstanding.
What happened to Sosei Group Corporation’s price movement after its last earnings report?
Sosei Group Corporation reported an EPS of -¥85.49 in its last earnings report, missing expectations of ¥73.9. Following the earnings report the stock price went down -0.913%.
Which hedge fund is a major shareholder of Sosei Group Corporation?
Currently, no hedge funds are holding shares in JP:4565
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Sosei Group Corporation
Sosei Group Corporation (4565) is a biopharmaceutical company based in Japan, specializing in the discovery and development of innovative medicines. The company focuses on drug development in the fields of neurology, respiratory diseases, and oncology, leveraging its expertise in drug design and development to create novel therapies. Sosei Group operates through various subsidiaries and has a strong pipeline of product candidates that target significant unmet medical needs.
4565 Company Deck
4565 Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented a mixed picture: strong commercial execution in Japan/APAC and meaningful pipeline progress (Phase II–ready assets and partner-led late-stage programs) are clear positives, supported by rising product sales and a profitable commercial unit. However, FY2025 was marked by material operating losses, a notable decline in milestone revenue, higher R&D spend, and one-off charges. Management has announced restructuring, cost-reduction targets (>10%), and a plan to refocus the U.K. discovery portfolio, with expectations that benefits will appear in H2 FY2026. Given the balance between encouraging commercial/pipeline momentum and significant near-term financial and execution risks, the overall tone is cautious and transitional: opportunities exist but require successful execution of BD, cost actions, and regulatory steps to translate into the company’s stated FY2026 profitability goals.View all JP:4565 earnings summariesTechnical Analysis
Peptidream
―
SanBio Co
―
Oncolys BioPharma, Inc.
―
Takara Bio Inc.
―
Japan Tissue Engineering Co., Ltd.
―
Options Prices
Currently, No data available
---